161 related articles for article (PubMed ID: 17273827)
1. Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
Hirose T; Shirai T; Ishida H; Ando K; Sugiyama T; Kusumoto S; Hosaka T; Nakashima M; Ohmori T; Adachi M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):267-74. PubMed ID: 17273827
[TBL] [Abstract][Full Text] [Related]
2. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
[TBL] [Abstract][Full Text] [Related]
3. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study.
Abou-Mourad Y; Otrock ZK; Makarem JA; Kattan JG; Farhat FS; Jalloul R; Mokaddem WT; Ghosen MG; Taher AT; Chehal AA; Shamseddine AI
J Med Liban; 2008; 56(1):16-21. PubMed ID: 19534086
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
7. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
8. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
Mok TS; Ho S; Chan G; Ho WM; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Lee Y; Lam KC
J Thorac Oncol; 2007 Sep; 2(9):838-44. PubMed ID: 17805062
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
10. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.
Matsubara N; Maemondo M; Inoue A; Ishimoto O; Watanabe K; Sakakibara T; Fukuhara T; Morikawa N; Tanaka M; Sugawara S; Nukiwa T
Respir Investig; 2013 Mar; 51(1):28-34. PubMed ID: 23561256
[TBL] [Abstract][Full Text] [Related]
12. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
[TBL] [Abstract][Full Text] [Related]
14. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.
Molina JR; Nikcevich D; Hillman S; Geyer S; Drevyanko T; Jett J; Verdirame J; Tazelaar H; Rowland K; Wos E; Kutteh L; Nair S; Fitch T; Flynn P; Stella P; Adjei AA
Cancer Invest; 2006; 24(4):382-9. PubMed ID: 16777690
[TBL] [Abstract][Full Text] [Related]
15. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Fujimoto N; Kiura K; Takigawa N; Fujiwara Y; Toyooka S; Umemura S; Tabata M; Ueoka H; Tanimoto M
Acta Med Okayama; 2010 Feb; 64(1):33-7. PubMed ID: 20200582
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
19. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Takeda K; Negoro S; Kudoh S; Okishio K; Masuda N; Takada M; Tanaka M; Nakajima T; Tada T; Fukuoka M
Br J Cancer; 1999 Mar; 79(9-10):1462-7. PubMed ID: 10188891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
